Physician profile
Helen Dinkelspiel Eshed
NPI 1215195516
$34,797.05
in general payments reported to CMS, 2019-2025
23 companies · $24K in 2025
The $24K reported for 2025 was more than what 94% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.31 · 2021: $90.31 · 2022: $5.99 · 2023: $317 · 2024: $11K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $26K · Consulting Fee: $3,375 · Travel and Lodging: $3,095 · Food and Beverage: $2,097.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26,115.50 |
| Consulting Fee | $3,375.00 |
| Travel and Lodging | $3,094.96 |
| Food and Beverage | $2,096.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $33,458.18 | 2024-2025 | |
| Immunogen, INC. | $275.20 | 2023 | Elahere |
| Myriad Genetic Laboratories, INC. | $161.96 | 2021-2025 | Myrisk, Mychoice Cdx |
| Astrazeneca Pharmaceuticals Lp | $151.09 | 2019-2025 | Imfinzi, Lynparza |
| Merck Sharp & Dohme LLC | $150.89 | 2023-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Glaxosmithkline, LLC. | $94.72 | 2024-2025 | Jemperli, Zejula |
| Incyte Corporation | $85.88 | 2024-2025 | Monjuvi, Jakafi |
| Janssen Biotech, INC. | $82.42 | 2024-2025 | Talvey, Darzalex, Tecvayli |
| Eisai INC. | $50.16 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $42.62 | 2024 | |
| Astellas Pharma US INC | $39.21 | 2025 | Veozah |
| Edwards Lifesciences Corporation | $39.04 | 2024 | Hemosphere |
| Tempus Ai, INC | $26.04 | 2024 | |
| Daiichi Sankyo INC. | $23.83 | 2025 | Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $22.17 | 2024 | Alunbrig |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aveo Pharmaceuticals, INC. | $19.60 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $19.09 | 2025 | Libtayo |
| Ipsen Biopharmaceuticals, INC | $18.61 | 2025 | Onivyde |
| Agios Pharmaceuticals, INC. | $16.17 | 2024 | |
| Jazz Pharmaceuticals INC. | $14.18 | 2025 | |
| Clovis Oncology, INC. | $5.99 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Helen Eshed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.